RxDoctor Payments DataLook up a doctor →

Daniel Kuritzkes, MD

Internal Medicine · Boston, MANPI 1114917416

Payments from drug & device makers

$2,083,049in general payments, 2019–2025

Across 357 payments — averaging $5834.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$863K
  • Novartis$605K
  • Viiv Healthcare Company$343K
  • Merck$161K
  • GSK$59K
  • Shionogi Inc$21K
  • plus $31K from 7 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead54$862,983
Novartis3$605,277
Viiv Healthcare Company146$343,477
Merck88$160,708
GSK28$59,035
Shionogi Inc19$20,589
AbbVie4$12,384
Modernatx, Inc.4$7,083
Pfizer3$3,675
Theratechnologies Inc.2$3,142
Roche Diagnostics Corporation2$2,953
Janssen Scientific Affairs, LLC3$882
Janssen Products, LP1$860

How this compares

$2,083,049 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$11,349
Medicare patients
46
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →